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Summary
Nerve cells of the central nervous system (CNS) are
distinct from the peripheral nervous system (PNS)
in that they are not capable of regenerating after
injury (Purves, D. et al. 2001). In recent studies,
scientists have discovered that the agents causing
this inability to regenerate are myelin-derived
protein inhibitors that form three families—MAG,
OMgp, and Nogo with a common receptor, NgR
(GrandPre, T. et al. 2000). Through alternative
splicing and use of two promoters, the Nogo gene
accounts for three proteins: Nogo-A, Nogo-B, and
Nogo-C. Recent in vivo studies on Nogo-A-
(Simonene, M. et al. 2003) and Nogo-A/B-/- mice
(Kim, J. et al. 2003) have shown potential for
regeneration of axons after injury. However, in the
field of neuroregeneration, the Nogo controversy
has led to a race to define exactly what role Nogo
and other inhibitory molecules play. The
controversy’s underlying basis is the fact that
axonal regeneration in Nogo-A- mice created by
Martin E. Schwab’s lab (Simonene, M et al. 2003) is
only modest, while axonal regeneration in Nogo-
A/B-/- mice created by Stephen M. Strittmatter’s lab
(Kim, J. et al. 2003) is significant yet decreases
upon age. In this proposal, we will develop a Nogo-
B knockout from Schwab's Nogo-A- mice to
alleviate the discrepancies in levels of axonal
regeneration seen in Schwab’s and Strittmatter’s
mice. Next, we will address the issue of minimal
axonal regeneration in the older mice (>11 weeks)
from Strittmatter’s lab (Kim, M. et al. 2003). The
functionality of MAG has been reported to have a
minor role as a secondary inhibitor of axonal
regeneration in vitro and in vivo. However, the
effect of OMgp has not yet been studied in vivo,
and we hypothesize that the minimal axonal
regeneration seen in the older mice (>11 weeks)
from Strittmatter’s lab is caused by OMgp
expression in the older mice. We will first assess
levels of OMgp expression in younger (6-11 weeks)
and older (>11 weeks) wild type mice. We will also
create knock out mice for OMgp- and OMgp/Nogo-
A/Nogo-B-/-/- to test the extent of axonal
regeneration. Finally, the effect of OMgp
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overexpression in the inhibition of axonal
regeneration will be tested using conditional
transgenic Nogo-A/B-/- mice that overexpress
OMgp.
Specific Aims
O n e :  Creation of double knockout Nogo-A/B-/-
mouse from Schwab’s Nogo-A- mice: Is Nogo-B
acting as a secondary inhibitor of axonal regeneration?
Two: Test for differential expression of OMgp in
younger and older mice: Does a difference exist in
the expression of OMgp in young (6-11 weeks) and old
(>11 weeks) mice?
T h r e e : Creation of OMgp and Nogo-A/Nogo-
B/OMgp-/-/- knock out mice: Will inactivation of Nogo-
A, Nogo-B, and OMgp increase axonal regeneration
after spinal cord injury?
Four: Creation of OMgp transgenic mice to evaluate
if axon regeneration is reduced further: W i l l
overexpression of OMgp in Nogo-A/B-/- mice inhibit
axonal regeneration?
Introduction
Spinal Cord Injury (SCI) in CNS is the clearest example
of a condition in which axonal damage leads to a
significant functional disability despite minimal neuronal
death (Kim, J. et al. 2003). In the US, 7,600-10,000
cases of SCI accumulate each year (Woolf, C. 2003).
Once severed, major axon tracts such as those in the
spinal cord never regenerate (Purves, D. et al. 2001).
The devastating consequences of these injuries (loss of
movement and the inability to control basic bodily
functions) have lead neuroscientists to seek ways of
restoring the connections of severed axons (Purves, D.
et al. 2001).
Aforementioned, axons in the mammalian
central nervous system (CNS) do not spontaneously
regenerate following injury; and consequently, there is
little functional recovery (Purves, D. et al. 2001). This
differs from the response of injured axons in the adult
peripheral nervous system (PNS), which do regenerate
after injury (Purves, D. et al. 2001; Fournier, A. et al.
2001). Damage to axonal tracts in adult CNS triggers a
very different response than in the PNS (Fournier, A. et
al. 2001). As axons and their myelin sheaths break
down distal to the site of injury, the removal of their
debris is relatively slow (sometimes persisting for many
weeks) and inefficient (Purves, D. et al. 2001). Proximal
to the site of injury, neurons fail to activate growth
related genes and associated proteins that are
expressed during development and successful
regeneration in the PNS (Purves, D. et al. 2001). The
lack of regeneration is due to a combination of factors
including death of injured neurons, reduced capacity of
adult neurons to grow when injured, lack of the
necessary trophic factors to support growth, and the
presence of an environment hostile for any growth
(Woolf, C. 2003). Components of this hostile
environment include astrocytes and the myelin
membrane, which interfere with regeneration at the site
of injury (Woolf, C. 2003). Astrocytes form the growth
associated astroglial scar consisting of tenascin,
keratin, and CSPGs, all of which have been shown to
inhibit axonal growth in vitro (Fournier, A. et al. 2001).
Central myelin produced by oligodendrocytes is also a
powerful suppressor of axonal growth (Fournier, A. et
al. 2001).
The role of axonal environment in
regeneration was first explored by Albert Aguayo’s lab
(Vidal-Sanz, M. et al. 1987). They showed that the optic
nerve located in CNS regenerates and restores the
appropriate synaptic connections to the superior
colliculus after injury when segments of the sciatic
peripheral nerve were grafted into CNS sites of the
optic nerve (Vidal-Sanz, M. et al. 1987). Failure of CNS
neurons to regenerate is thus not due to an inability to
sprout new axons, but rather due to something in the
local environment that inhibits growth cones from
forming and axons from extending (Purves, D. et al.
2001). This demonstration that CNS axons can
sometimes regenerate successfully sparked an
intensive effort by many labs to discover axonal
regeneration inhibitors in the local environment (Purves,
D. et al. 2001).
In recent studies, axonal regeneration
inhibitors have been identified as myelin-derived protein
inhibitors forming three families--Myelin-Associated
Glycoprotein (MAG), Oligodendrocyte-Myelin
glycoprotein (OMgp), and Nogo with a corresponding
Nogo receptor (NgR) (Kim, J. et al. 2003). MAG inhibits
axon growth in vitro (Liu, B. et al. 2002). In vivo, MAG
has been shown to limit axon regeneration under
certain conditions, although regeneration remains poor
in the absence of MAG (Kim, J. et al. 2003). Rather
than limiting axonal growth, the function of MAG
physiologically appears to be the maintenance of
myelin stability through axoglial contact (Kim, J. et al.
2003). Mice lacking MAG have delayed myelination,
myelin splitting and redundancy, and decreased
thickness of periaxonal cytoplasmic collar of
oligodendrocytes, which leads to axon degeneration
over time (Kim, J. et al. 2003). OMgp is predominantly
localized on the surfaces of oligodendrocytes (Wang, K.
et al. 2002). It is a glycosylphophatidylinositol (GPI)-
anchored CNS myelin protein and a potent inhibitor of
neurite outgrowth in vitro (Wang, K. et al. 2002). In
addition, an OMgp-enriched myelin fraction has been
shown to inhibit neurite outgrowth more than a MAG-
enriched myelin fraction (Wang, K. et al. 2002). The
effect of OMgp has not yet been studied in vivo (Wang,
K. et al. 2002). Another myelin-derived axon growth
inhibitor is Nogo or Reticulon 4 (GrandPre, T. et al.
2000). Analysis of Nogo expression reveals three
mRNA species derived from two promoters and
alternative splicing of one gene (GrandPre, T. et al.
2000). Nogo-A, found in neurons, is the major protein
species in oligodendrocytes, and is produced
embryonically by skeletal muscles (Kim, J. et al. 2003).
Nogo-B is a less abundant form found in the brain (Kim,
J. et al. 2003). Nogo-C is found in neurons and
produced in adult skeletal muscles, but it is not thought
to be a major axonal regeneration inhibitor as it is not
found in oligodendrocytes and myelin (Kim, J. et al.
2003). All isoforms of Nogo share a common C-terminal
domain of 188 amino acids (He, X.L. et al. 2003). A 66
amino acid sub domain, expressed on the surface of
the three forms can potentially inhibit axon growth by
binding to an axonal Nogo-66 receptor (NgR)
expressed by CNS neurons (He, X.L. et al. 2003).
MAG, OMgp, and Nogo have been shown to bind with
high affinity to NgR (He, X.L. et al. 2003). The three
ligands for NgR are structurally quite unrelated—Ig-like
domains for MAG, a curved leucine-rich repeat array for
OMgp, and a compact globule for Nogo-A, B, C— all
converge on a selection of distinct binding hotspots on
NgR (Fournier, A. et al. 2001). In vitro activity of Nogo
and selective expression of Nogo in CNS but not PNS
myelin are consistent with its role as a myelin-derived
inhibitor of axonal regeneration after injury (Purves, D.
et al. 2001). Several lines of evidence support the role
for Nogo-A/B/C in limiting CNS axon regeneration (Kim,
J. et al. 2003).
However, three studies on Nogo, along with
the aforementioned, report a stark divergence in
regeneration phenotype leading to the Nogo
controversy in defining exactly what role Nogo and
other inhibitory molecules play (Woolf, C. 2003). The
controversy’s underlying basis is the fact that axonal
regeneration in Nogo-A- mice created by Martin E.
Schwab’s lab (Simonene, M. et al. 2003) is only
modest, while axonal regeneration in Nogo-A/B-/- mice
created by Stephen M. Strittmatter’s lab is significant
but decreases upon age (Kim, J. et al. 2003; Zheng, B.
et al. 2003; Woolf, C. 2003).
We hypothesize that differences in the extent
of axonal regeneration in Martin E. Schwab lab
(Simonene, M. et al. 2003) and Stephen M. Strittmatter
lab (Kim, J. et al. 2003) mice respectively are due to the
presence of Nogo-B, which may be serving as a
compensatory, secondary axonal inhibitor. Therefore,
we will create a knock out of Nogo-B from Schwab’s
Nogo-A- mice to resolve the discrepancy in levels of
axonal regeneration seen in Schwab’s and Strittmatter’s
mice. We also propose that the age-dependant
inhibition seen in Strittmatter’s mice is due to increased
inhibition of OMgp in older (>11 weeks) Nogo-A/B-/-
mice. Therefore, we will first assess the expression of
OMgp in younger and older mice. Secondly, we will
create OMgp-/- and OMgp/Nogo-A/Nogo-B-/-/- mice to
completely alleviate this age dependant discrepancy in
axonal regeneration. Finally, we will create transgenic
mice from Nogo-A/B-/- mice that overexpress OMgp to
determine whether it can inhibit axonal regeneration
upon overexpression.
Aim One: Creation of double knockout Nogo-A/B-/-
mouse from Schwab’s Nogo-A- mouse
Rationale:  Martin E. Schwab’s laboratory (Simonene,
M. et al. 2003) demonstrated a compensatory increase
in Nogo-B axonal inhibitor expression following
knockout of Nogo-A.  Considering that axonal
regeneration following spinal chord injury (SCI) in these
Nogo-A- mice was minor compared to that observed in
the Nogo-A/B-/- mice of Strittmatter’s laboratory (Kim et
al., 2003), it is possible that Nogo-B may be inhibiting
axonal regeneration.  To demonstrate that Nogo-B, in
addition to Nogo-A, significantly inhibits axonal
regeneration following SCI, a Nogo-A/B-/- double
knockout mouse will be created from Schwab’s existing
Nogo-A- knockout mouse.  We expect that axonal
regeneration following SCI will be more extensive in our
Nogo-A/B-/- mice as compared to Schwab’s Nogo-A-
mice. The double knockout mouse will be created using
a gene replacement approach similar to that employed
by Schwab’s laboratory (Simonene, M. et al. 2003),
which will selectively abolish Nogo-B expression.
Southern, Northern, and Western blot analyses will be
performed to ensure successful knockout of Nogo-B.
The extent to which Nogo-B is responsible for a
significant fraction of myelin-dependant inhibition in
vitro will be determined by examining the growth of wild
type axons in the presence of Nogo-A- and Nogo-A/B-/-
derived myelin.  The inhibitory affect of Nogo-B will be
assessed in vivo, by examining the extent of axonal
regeneration after dorsal hemisection injuries (Kim et
al., 2003) in both knockouts.  Expected improvement in
locomoter recovery by Nogo-A/B-/- mice compared to
Nogo-A- mice will solidify the characterization of Nogo-
B as an inhibitory agent of post SCI axonal
regeneration.
Strategy A: Creation of the Double Knockout Mouse
The technique used by Schwab, M.E. et al (Simonene,
M. et al. 2003) to create the Nogo-A knockout mice will
be adapted to create the Nogo-A/B-/- mice.  Nogo-A-
mice will be obtained from Schwab’s lab, and they will
serve as controls as well as tools for creating the Nogo-
A/B-/- double knockout mice.  A Nogo-B specific
replacement vector will be   obtained from the
Omnibank Sequence Tag database (Lexon genetics
Inc.). The vector will then be used to design a plasmid
containing a fusion gene (Kim et al., 2003) of IRES-β-
geo and neomysin genes such that it could be targeted
to the Nogo-B locus.  Thus, when the genomic DNA of
Nogo-A- mouse is transformed in a neomycin selection
media, the Nogo-B gene will be replaced by our gene
construct (Figure 1). This newly synthesized DNA
fragment will be added to a targeting vector, which will
in turn be introduced into a culture of Nogo-A- mouse
embryonic stem (ES) cells.  Following growth selection
with neomysin, the surviving ES cells will be injected
into a blastocyst and introduced into pseudopregnant
female mice.  The resulting chimeric male offspring will
be bred with Nogo-A- female mice to produce
heterozygous Nogo-A/B-/-offspring, which will then be
identified and interbred to generate the homozygous
Nogo-A/B-/- mice.
(Homologous Recombination method (and Knockout Mouse), 9/24/03)
(http://www.bio.davidson.edu/courses/genomic/method.html
Expected Results
The A1 generation is expected to be 50% heterozygous
mice (GA) for the fusion gene construct (Fig. 2A) after
crossing wild type mice (G) and mice with cells
containing the fusion gene (A). The A1 generation, a
cross between the heterozygous mice, is expected to
generate 25% homozygous mice (AA) for the fusion
gene construct (Fig. 2B).
Strategy B: Verifying knockout mice in vitro   
Method 1: Southern Blot Analysis
Homologous recombination will first be confirmed
through Southern blot analysis of the mouse DNA.
Various restriction enzyme sites on the mouse DNA will
be determined.  Enzymes with restriction sites specific
to the locus of the gene (Enzyme A or B) that is also
present on the Nogo-A/B-/- mouse DNA (Enzyme A at 3’
end or Enzyme B at 5’ end) (Figure 1).  Genomic DNA
will be extracted using the DNeasy Tissue Kit (Qiagen),
and techniques given by Amersham Biosciences will be
applied to perform a restriction enzyme digest with
either enzyme A or B, and probing of the DNA with the
32P-labeled respective 3’ or 5’ probe.  The mixture of
DNA fragments, cleaved by the specific restriction
enzymes, will be run on an agarose gel and transferred
to a nylon membrane.  A probe that is complementary
to either the 3’ or 5’ DNA sequence will be generated
using PCR and allowed to undergo hybridization
(Amersham Biosciences).
Expected Results
Results should reveal that the β-geo gene is present
only in the Nogo-A/B-/- knockout mouse, while the
Nogo-B gene is present both in the wild type and Nogo-
A- control mice.  This will be indicated by the different
fragment sizes generated by the restriction enzyme
digest using either Enzyme A or B.  The large enzyme
fragment (_-geo) should only be generated for both the
wild type and control mice, while the small fragment
(Nogo-B) should be generated only for the knockout
Nogo-A/B-/- mice.
Method 2: Northern Blot Analysis
A Northern blot analysis will be done to confirm whether
or not the Nogo-B gene is expressed.  A 32P-labeled
probe will be developed (Amersham Biosciences) from
a cDNA library of Nogo-B (Origene Technologies) that
will hybridize with the Nogo-B mRNA.  Total brain RNA
extracts will be isolated and purified from each of the 3
types of mice (WT, Nogo-A-, and Nogo-A/B-/-) using the
RNeasy Midi Kit (Qiagen).  Liver cell mRNA not
expressing Nogo-B will also be extracted and used as
the negative control.  RNA extracts will be isolated,
eloectrophoresed on an agarose gel, and transferred to
a nylon membrane, as described by Amersham
Biosciences.  β-actin mRNA will be used as the loading
control (Kim, J., et al., 2003), considering that it is found
in all eukaryotic cells including nervous system cells,
and its quantification is not dependant upon age
(Alberts, B. et al. 1998).
Expected Results
Results from the Northern blot analysis should
demonstrate complete absence of Nogo-B in the
negative control mRNA and in the mRNA of the adult
brain of Nogo-A/B-/- mice.  Nogo-B mRNA should be
expressed in the brains of both wild type and Nogo-A-
control mice.  All mouse mRNA extracts should express
β-actin.
Method 4: Western Blot Analysis
A Western blot will be performed on adult cerebral
cortex extracts from each of the three mice. The
primary anti-Nogo N terminus antibody, followed by an
HRP conjugated goat anti-rabbit secondary antibody,
used by Zheng, B., et al., 2003, will be used for the
Western blot.  Protein samples will be electrophoresed
on a polyacrylamide gel, transferred onto a
nitrocellulose membrane, and hybridized with the
primary and secondary antibodies (Amersham
Biosciences).  A liver cell native control will be used,
and myelin-associated glycoprotein (MAG) antibody will
be used as the loading control (Kim, J., et al., 2003).
Expected Results
The Western blot should confirm that Nogo-B protein is
synthesized in both wild type and Nogo-A- control mice
and not in Nogo-A/B-/- knockout mice.  Considering that
MAG protein is produced in all cell types, the Western
blot should confirm its expression in all control and
experimental tissues.
Strategy C: Verifying knockout mice in vivo
Method 1: Analysis of Brain histology
Effects of an absence of the Nogo-B gene and
presence of the β-geo- neomysin fusion gene construct
in knockout mice will be determined by comparing brain
size and gross brain anatomy of the recombinant mice
to wild type and Nogo-A- mice through staining and
imaging specific brain sections.  Major brain nuclei in
addition to neuronal layers of the cerebral cortex and
cerebellum will be specifically analyzed through the
staining of coronal sections with hematoxylin and eosin
(Kim et al., 2003). Because the Nogo gene insertion
places Lac-Z (consistent with IRES-β-geo) under the
control of the Nogo-B regulatory elements, those cells
that would normally express Nogo-B can be identified
by examining the cells for β-galactosidase activity in X-
gal cultures.  Luxol fast blue will be used to stain for
total myelin content and location in the cerebral and
cerebellar cells of Nogo-A/B-/-, wild type, and Nogo-A-
control mice to determine if oligodendrocyte formation
and survival following recombination are consistent with
that of wild type and Nogo-A- mice, marked by CNPase
(Strittmatter, S.M. et al., 2003).
Expected Results
Coronal sections of the cerebral cortex, stained with
hematoxylin and eosin (Fig. 6A and 6B) or X-gal
(Fig.6C) should reveal brain nuclei that are
indistinguishable from those of wild type and Nogo-A-
control mice.  The number and position of β -
galactosidase-positive cells in this section should be
very similar to that of Nogo-B-positive cells in the
cerebral cortex of wild type and control mice (Grandpre,
et al., 2000; Wang, et al., 2002a), indicating that
neuronal placement and survival is normal in adult
Nogo-A/B-/- mice.  Parasaggital cerebellar sections from
Nogo-A/B-/- mice, stained with hematoxylin and eosin
(Fig. 6D and 6E) should be indistinguishable from wild
type and control mice.  Patterns of oligodendrocyte
distribution and location in sections of young adult mice
lacking Nogo-B, stained with Luxol fast blue (Fig. 6G
and 6H), are expected to be similar to those of wild type
and Nogo-A- mice (Grandpre, et al., 2000; Wang, et al.,
2002a).  Cells in sections stained with X-gal (Fig. 6C,
6F and 6I) should all indicate blue color thereby
indicating the expression of the β-galactosidase gene.
Method 2: Behavioral Analysis
To determine whether there are any effects on axonal
performance that might change neuronal function and
mouse behavior, we will perform a qualitative neuronal
examination on control and experimental mice using the
rotarod test, in which mice will be placed on the
Technical Scientific Equipment rotating rod, moving at
constant acceleration (Kim, J., et al., 2003).  After initial
training, on consecutive days, the length of time that the
mice are able to remain on the rod will be recorded
(Kim, J., et al., 2003).
Expected Results
The experiment should reveal no observable difference
between the wild type/Nogo-A- control and Nogo-A/B-/-
experimental mice (Fig.7).  No differences should be
observed between mice with and without Nogo-B in the
rotarod experiment.
Strategy C: Assessing whether Nogo-A/B-/- Myelin
Inhibits Axonal outgrowth in vitro
Nogo-B is produced by oligodendrocytes, which are
present in the myelin. In order to assess the effects of
Nogo-B deletion on axonal outgrowth, we will compare
the growth of wild type axons in cultures containing
myelin derived from Nogo-A- control mice and Nogo-
A/B-/- experimental mice. Two different assays will be
used for this investigation:
Method 1: Neurite Outgrowth Assay
The neurite outgrowth assay is used here to determine
the effect of an absence of Nogo-B on the extent to
which wild axons sprout.  The protocol for the assay will
be adapted from Kim, J., et al., 2003.
Expected Results
The absence of Nogo-B in Nogo-A/B-/- myelin (Fig. 8C)
and lack any inhibitor in control (Fig. 8A) should result
in extensive neurite outgrowth, while the presence of
Nogo-B in Nogo-A- myelin (Fig. 8B) should leads to
modest axonal regeneration.
Method 2: Growth Cone Collapse Assay
The growth cone collapse assay is used here to
measure the effect of the absence of Nogo-B on the
branching of wild axons by investigating the extent to
which myelin derived from Nogo-A-, and Nogo-A/B-/-
mice cause wild type axons to maintain growth cones,
which is an indication of axonal regeneration capacity.
The protocol for the assay will be adapted from Kim, J.,
et al., 2003.
Expected Results
The absence of Nogo-B any in Nogo-A/B-/- (Fig 9C) and
any inhibitor in the control (Fig 9A)  derived myelin, is
expected to lead to a larger number of growth cones
when compared to axons cultured in Nogo-A- myelin
(Fig 9B).
Strategy D: Investigation of Axonal Sprouting After
Spinal Chord Injury in Nogo-A/B-/- Mice
Method
The effects that a lack of myelin dependent inhibition,
due to the absence of Nogo-B, may have on axonal
regeneration following SCI will be explored in Nogo-A-
and Nogo-A/B-/- mice, as was done by Kim, J., et al.
2003.  A dorsal hemisection injury will be introduced at
the T7 level of the spinal chord in accordance with
Animal Care and Use Committee guidelines.  Resulting
axonal sprouting will be investigated using Biotin
dextran amine (BDA) injections at sites rostral and
caudal to the SCI (Kim, J., et al., 2003).  Female mice
will be anesthetized, and laminectomies performed at
the T7 level, exposing the spinal cord.  A dorsal
hemisection will be performed using the tip of a 32-
gauge needle, which should cause complete
interruption of the dorsal and dorsolateral cortispinal
tracts (CSTs).  Severed skin and muscle layers will be
sutured. BDA molecular probes will be injected through
a hole drilled in the skull of the mice into the brain area
overlying the sensorimotor cortex in order to trace the
corticospinal tract (Kim, J., et al., 2003. Mice will be
cared for and treated with antibiotics for several days
following operation.  Spinal cords will be dissected at
approximately 20 days post SCI, processed as
described by Kim, J., et al. (2003), sectioned, and
examined with a 20x objective lens to obtain counts and
projection patterns of regenerated fibers highlighted
through BDA staining.  For rostral and caudal
investigations, coronal sections at the T4 and C8
vertebrae of the spinal cord will be observed




Coronal sections at C6 and T2 should reveal an
absence of axonal sprouting rostral and caudal
respectively to SCI in wild type mice (Fig.10A and 10D).
The red arrows indicate the corticospinal tract stained
with BDA, injected from the cerebrum at the
contralateral position of the spinal cord.  Moderate
axonal sprouting (indicated by black arrows) should be
observed in Nogo-A- mice rostral and caudal to SCI
(Fig.10B and 10E), while extensive sprouting should be
observed rostral and caudal to SCI in the Nogo-A/B-/-
mice (Fig.10C and 10F).  Such results may consolidate
Nogo-B as a key player in myelin-derived inhibition of
CNS neuronal growth.
b) Sagittal Studies
Sagittal sections are expected to reveal an absence of
axonal sprouting rostral and caudal to SCI in wild Type
mice (Fig.11A).  The sagittal sections of the spinal cord
of Nogo-A- mice however should reveal moderate
axonal sprouting (indicated by black arrows) (Fig.11B)
as was demonstrated by Kim, J., et al., 2003, and
extensive axonal sprouting is expected in the spinal
cord of Nogo-A/B-/- mice (Fig.11C).  The red and green
arrows indicate the injury site at T4 and the
corticospinal tract stained with BDA respectively.
Strategy E: Assessment of Functional Recovery of
Locomotor Activity Following Spinal Chord Injury
Method
Correlation of extensive long-distance axonal
regeneration with functional recovery after the
hemisection injury in the recombinant mice will be
assessed using the BBB score, a standardized open-
field measure of locomotor function after SCI (Basso, et
al., 1996). The test is designed to rate the movement of
a mouse on a scale from 0 to 21, 0 being the lowest
and 21 being the highest.  It is comprised of placing a
mouse inside of a pool with a diameter of approximately
90cm and walls 10cm high (Scheff et al, 2002).  The
mouse is observed for a 4 minute period by two
separate observers, who base the score on a variety of
critera (Scheff et al, 2002).  The animals are tested
starting as soon as 1 day post-injury, testing typically
occurs at 1 week intervals for 6-9 weeks, but can be
monitored as frequently as daily. (Scheff et al, 2002).  A
score of 0 is awarded to a mouse who shows no hind
limb movement, and a score of 21 is awarded to a
mouse who displays coordinated limb movement,
consistent planar stepping, consistent toe clearance,
parallel paw position throughout the step cycle,
consistent trunk stability, and the tail constantly pointed
upwards (Scheff et all, 2002).
E x p e c t e d  R e s u l t s
Comparison of open field locomotor activity between
Nogo-A- and Nogo-A/B-/- mice should demonstrate
significantly lower BBB scores achieved by Nogo-A-
mice than by Nogo-A/B-/- mice.  Hence, recovery of
locomoter performance should be accelerated in Nogo-
A/B-/- mice, which would be most likely attributed to
increased axonal growth if observed.
Aim Two: Test for differential expression of OMgp
in younger (6-11 weeks) and older (>11 weeks) mice
Rationale:  It is possible that age affects axonal
sprouting in Nogo-A/B-/- mice. All of Strittmatter’s young
adult Nogo-A/B-/- mice exhibited pronounced CST axon
sprouting proximal to the site of injury (Kim, J. et al.
2003). However, preliminary studies indicate that
sprouting may be restricted at older ages in the Nogo-
A/B-/- mice (Kim, J. et al. 2003). Thus, CST sprouting
may occur only when SCI occurs at the young adult
stage (6-11 weeks) (Kim, J. et al. 2003). If
substantiated, this could indicate that neurons in older
animals have either a reduced capacity to grow or that
some non-Nogo growth inhibitory factor is expressed
increasingly with age (Woolf, C. 2003). However, any
implication of this in human adult CNS lesions remains
unknown (Woolf, C. 2003). Therefore, we propose that
the differential axonal sprouting in young (6-11 weeks)
and adult (>11 weeks) mice is due to an inhibitor that is
expressed increasingly with age. A recent study
conducted by Wang, K. et al. 2002 reports that OMgp-
enriched myelin fraction inhibits neurite outgrowth more
than a MAG-enriched myelin fraction. OMgp is highly
expressed by mature oligodendrocytes positive for
myelin basic protein (MBP) which are enriched with
axon-adjacent myelin layers (Wang, K. et al. 2002). The
effect of OMgp has not yet been studied in vivo (Wang,
K. et al. 2002). In order to determine if OMgp
expression is age-dependant, we will perform Northern
and Western analyses, immunohistochemistry, and in
situ hybridization to evaluate wild type OMgp levels and
locations in vivo within mice ages 6 weeks, 11 weeks,
and 14 weeks.
Strategy A: Northern Blot analysis of mice
Method
A Northern blot will be done (as explained in Aim 1,
Strategy B, Method 2) to evaluate whether or not the
OMgp gene is expressed in wild type mice of ages 6
weeks, 11 weeks, and 14 weeks. A probe will be
developed for the OMgp gene from a cDNA library
(Origene Technologies), where a fragment of OMgp
DNA sequence will be used to create a 32P-labeled
probe through PCR, which will hybridize with the OMgp
mRNA (GrandPre, T. et al. 2000). ß-actin probe (Kim, J.
et al. 2003) will be used as the loading control.
Expected Results
Northern blotting should reveal expression of OMgp in
all ages (6, 11, and 14 weeks) of the wild type mice.
Strength of hybridization of the probe should increase
with age to account for age-dependant inhibition seen
in Strittmatter’s Nogo-A/B-/- mice (Figure 13). ß-actin
expression should be consistent through all ages of
mice.
Strategy B: Western Blot analysis of mice
Method
A Western blot will be done to reveal the presence or
absence of the OMgp protein within wild type mice of
ages 6 weeks, 11 weeks, and 14 weeks. Anti-OMgp
antibodies will be used to detect enrichment of OMgp
protein in brain extracts (Wang, K. et al. 2002). Myelin-
Basic protein will be used as the loading control
considering that it is found in nervous system cells, and
its quantification is not dependant upon age (Kim, J. et
al. 2003).
Expected Results
Western blotting is expected to indicate the occurrence
of protein synthesis at a greater rate in correlation with
increased age in wild type mice (Figure 14). The OMgp
antibody should give a stronger signal in adult
compared to young mice. Myelin Basic Protein should
indicate consistent expression through all ages of mice.
Strategy C: Immunohistochemistry analysis of mice
Method
Immunohistochemistry analysis will be used to detect
OMgp expression in spinal cord and several brain
tissues (cerebral cortex, cerebellum, and corpus
callosum) of the wild type mice of ages 6 weeks, 11
weeks, and 14 weeks. Protein expression will be
assessed using the primary and secondary antibodies
developed by Wang, K. et al. 2002. Tissue samples will
be prepared and sections developed from anesthesized
mice, and OMgp expression will fluoresce from staining
by antibodies (Wang, X. et al. 2002). Lung tissue from
wild type mice will be used as a control since OMgp is
an oligodendrocyte-myelin glycoprotein and should only
be found in nervous system cells (Kim, J. et al. 2003).
Expected Results
The immunohistochemistry analysis should indicate
evident OMgp protein expression in the spinal cord,
cerebral cortex, cerebellum, and corpus callosum of all
ages of wild type mice. OMgp should immunofluoresce
by primary and secondary antibodies in larger
quantities in correlation with increasing ages of mice to
account for age-dependant inhibition. OMgp should not
immunofluoresce in lung tissue considering that OMgp
expression should only occur in the CNS (Figure 15).
Strategy D: In Situ Hybridization analysis of mice
Method
In situ hybridization analysis will be used to detect
OMgp expression in the spinal cord and several brain
tissues (cerebral cortex, cerebellum, and corpus
collasum) of wild type mice of ages 6 weeks, 11 weeks,
and 14 weeks. In situ hybridization reveals whether the
mRNA is translated into protein even if the protein, in
that cell is not expressed (Nieto, M. et al. 1996). In a
previous study, OMgp was reported to be highly
expressed by mature oligodendrocytes positive for
myelin basic protein (MBP), and enriched in the axon-
adjacent myelin layers (Wang, K. et al. 2002). Hence,
an in situ hybridization should reveal similar results.
Protein expression will be assessed using the same
probe as aforementioned (GrandPre, T. et al. 2000).
Tissue samples will be prepared similar to
aforementioned (Nieto, M. et al. 1996). Lung tissue
from wild type mice will be used as a control (Kim, J. et
al. 2003).
Expected Results
The in situ hybridization analysis is expected to
demonstrate OMgp expression in oligodendrocytes and
myelin evident in the spinal cord, cerebral cortex,
cerebellum, and corpus callosum of all ages of wild type
mice. OMgp should be hybridized by the probe and
expressed in profile in a similar manner to the CNS
tissue in immunohistochemistry analysis.  The tissue
should not express in lung tissue (Figure 16).
Aim Three: Creation of OMgp and Nogo-A/Nogo-
B/Omgp-/-/- knockout mice
Rationale: Based on the expected results from aim 1,
the most plausible reason for the modest axonal
regeneration in the mice from Schwab’s lab (Simonen
et al., 2003) is the action of Nogo-B acting as a
compensatory protein causing inhibition of axonal
regeneration. The expected results from aim 2 suggest
the possibility that OMgp acts as a potential inhibitor in
older mice. Therefore we propose to construct two
types of knockout mice to demonstrate the inhibitory
activity of Omgp on axonal regeneration in older mice
specifically. The Omgp gene will be knocked out, and
both younger (6-11 weeks) and older (>11 weeks) mice
will be analyzed for potential axonal regeneration after
SCI.  The main objective of this experiment is to
determine whether OMgp is the prominent inhibitor in
older mice. We expect axonal regeneration after SCI in
older mice (>11 weeks), but not in younger mice (6-11
weeks). We will then design a Nogo-A/Nogo-B/Omgp-/-/-
mice by knocking out OMgp in the mice designed in aim
1. The purpose of this experiment is to investigate the
role of Nogo-A and Nogo-B as potential inhibitors of
axonal regeneration besides OMgp in older mice. We
hypothesize that Nogo-A & B act as prominent
inhibitors in younger mice (7-11weeks) and that OMgp
is the prominent inhibitor in older mice (>11 weeks).
The success of both aims would be tested by in vitro
and in vivo techniques. In vitro studies include neurite
outgrowth and growth cone collapse assays, while in
vivo studies consist of histological analyses of coronal
and sagittal sections of the spinal cord following SCI.
Step: OMgp- Knockout Mice
Strategy A: Designing of the OMgp Knockout Mice
Method
Wild type mice will be obtained from Strittmatter’s lab
(Kim et al., 2003) and will serve as tools for designing
the triple knockout mice. The OMgp knock mice will be
generated by introducing a fusion gene construct will be
obtained from Strittmatter et al (Kim et al., 2003), which
expresses the β-geo and the neomycin resistant genes.
The gene construct will be placed before the OMgp
promoter through homologous recombination, by
modifying the gene construct will be further with
sequences of the actual OMgp gene (Wang, K. et al.
2002). The homozygous mice will be generated using
the gene construct as explained in aim 1, strategy A.
Strategy B: Verifying the genotype of the Knockout
Mice in vitro
Method 1: Northern Blotting
The OMgp gene, if disrupted by the neomycin-
galactosidae fusion gene, is not expected to produce
mRNA strand. Total brain RNA will be isolated from the
OMgp knock out mouse and hybridized with the same
OMgp specific probe used in Aim 2, Strategy A. Cell
extracts from the liver cells of the knockout mice will be
used for the loading control, and a β-actin specific
probe that will be obtained from Strittmatter (Kim et al.,
2003) will be used as the loading control.
Expected Results
Omgp protein is expected to be present in wild type
mice and absent in the brain extract and liver cells of
the OMgp-/- mice (Fig.17). Equal amounts of mRNA
content are expected to arise in both wild type and
knock out mice for the loading control (Fig. 17).
Method 2: Western Blotting
The western blot analysis will be conducted on total
brain lysate. The OMgp antibody for the western blot
will be obtained from Wang et al (Wang et al., 2003)
and will be hybridized as explained in aim 1, strategy b,
method 3.  Cell extracts from liver cells will be analyzed
for the negative control, and expression of MBP protein
will be analyzed using the MBP specific antibody
obtained from Strittmatter lab (Kim et al., 2003) for the
loading control.
Expected Results
If the neomycin gene successfully replaces the target
OMgp gene, the OMgp protein should not be produced
and will not bind to the OMgp specific antibody.
Therefore, we expect the lane to run blank in the knock
out mice (Fig. 18). Since, OMgp is expressed only
CNS, we also do not expect a signal for the liver cells.
We do however expect the expression of MBP in the
cells of both types of mice, considering that it is
commonly expressed in all CNS cells (Fig. 18).
Method 3: Analysis of Brain Histology
To ensure that the absence of OMgp gene is not
affecting the structure and general function of the brain,
hematoxylin, eosin, and luxol fast blue staining assays
(Kim et al., 2003) will be applied to the cerebral cortex,
cerebellum, and corpus callosum sections as explained
in aim 1, strategy c, method 1. The expression of β-
galactosidase gene will be also tested as explained in
aim 1, strategy c, method 1.
Expected Results
We expect that both the wild type and the knockout
mice will demonstrate similar brain histology
considering that we should not have affected any
proteins other than OMgp (Fig. 19). For the cells grown
in X-Gal plates, we expect to see blue coloration due to
the expression of the b-galactosidase gene (Fig.19).
b) Rotarod Test: The rotarod test was used to
compare the functional recovery of locomotor activity
following SCI in knockout mice compared to wild type
mice, and was performed as explained in aim 1,
strategy c., method 2.
Expected Results
Wild type and OMgp-/- mice are expected to behave
similarly in the rotarod test (Fig. 20).
Strategy C:  In Vitro Investigation of young (6-11
weeks) and adult (>11 weeks) OMgp Mice.
OMgp is produced by oligodendrocytes, which are
present in myelin. To investigate the different effects of
OMgp in younger (6-11 weeks) and older mice (>11
weeks), we will compare the growth of wild type axons
in cultures containing myelin derived from young and
old OMgp-/- mice. We will use two different assays for
this investigation:
Method 1: Neurite Outgrowth Assay
The neurite outgrowth assay will measure the extent to
which axons sprout and will be conducted as explained
in aim 1, strategy c, method 1.
Expected Results
We expect to see more neurite outgrowth in older
OMgp-/- mice compared to young OMgp-/- mice, due to
the presence of Nogo-A&B in younger mice (Fig. 21).
Method 2: Growth Cone Collapse Assay
The growth cone collapse assay will measure the
extent of axonal branching by specifically detecting the
number of growth cones in a culture. The protocol for
the assay will be adapted from aim 1, strategy c,
method 2.
Expected Results
We expect to see more growth cones in older OMgp-/-
mice (>11 weeks) compared to young OMgp-/- mice(6-
11 weeks) due to the presence of Nogo-A&B in younger
mice (Fig. 22).
Strategy D: In Vivo Investigation of the OMgp
knockout Mice
The most important part of the third aim is the
investigation of the axonal regeneration after SCI in
young (6-11 weeks) and old OMgp-/- mice (>11 weeks).




We expect to see more axonal sprouing in older OMgp-
/- mice (6-11 weeks) compared to younger OMgp-/- mice
(>11 weeks) due to the presence of Nogo-A&B in
younger mice (Fig. 23). We also expect the sprouting to
extend ipsilaterally and contralaterally to the CST
considering that factors that control the directions of
axonal growth are usually absent at the adult stages.
b) Sagittal Studies
We expect to see extensive axonal sprouting rostral
and caudal in both contralateral and ipsilateral
directions around SCI in older OMgp-/- mice and no
sprouting should be observed in younger OMgp-/- and
wild type mice due to the presence of Nogo-A and
Nogo-B.
Step 2: Nogo-A/Nogo-B/OMgp-/-/- Knockout Mice
Strategy A: Design of the Nogo-A/Nogo-B/Omgp-/-/-
Knockout Mice
The removal of OMgp in step 1 of aim 1 should
demonstrate OMgp as an axonal growth inhibitor in
older mice. Considering the presence of other inhibitors
like Nogo-A & B, the next logical step is to investigate
the extent of axonal regeneration following SCI in older
and younger Nogo-A/Nogo-B/OMgp-/-/- mice. We expect
to see extensive axonal sprouting as was seen by
Strittmatter et al., 2003 in the younger Nogo-A/Nogo-
B/OMgp-/-/- mice and a similar result as seen in step 1 of
aim 3 in older Nogo-A/Nogo-B/Omgp-/-/- mice. The
Nogo-A/B-/- mice used in the investigation of aim 1 will
be used for designing the Nogo-A/Nogo-B/OMgp-/-/-
mice.  The same fusion gene used in step 1 of aim 3,
which consists of the neomycin drug resistant gene and
β-geo gene will be put under the promoter of the OMgp
gene. The Nogo-A/Nogo-B/OMgp-/-/- mouse will be
created from the Nogo-A/B, consisting of the neomycin
drug resistant gene and the β-geo gene as explained in
aim 1, strategy A.
Strategy B: Verifying the genotype of the Nogo-
A/Nogo-B/Omgp-/-/-  Knockout Mice in vitro
Before proceeding with further investigation on the
knockout mice, it is necessary to test its phenotype both
in vitro and in vivo.  Therefore, we will conduct Northern
and Western blots, and histological and behavioral
studies on the Nogo-A/Nogo-B/OMgp-/-/- mice as
explained in aim 1, strategy b.
Method 1: Northern Blotting
Total brain RNA will be isolated and hybridized with the
OMgp specific probe used in aim 3, Strategy b, method
1 as explained in aim 1, strategy b, method 1. A
negative control for the assay will be conducted on cell
extracts from the liver and a loading control for testing
the efficiency of the assay will be conducted using the
β-actin specific probe used in aim 3, strategy b, method
1.
Expected results
Signals for OMgp are expected to be seen in wild type
extracts, but not in brain and cell extracts of the Nogo-
A/Nogo-B/OMgp-/-/- mice (Fig. 25).  Also, transcription of
β-actin mRNA should be observed in both wild type and
the triple knockout mice.
Method 2: Western Blotting
A western blot will be performed to test the existence of
OMgp protein in Nogo-A/Nogo-B/OMgp-/-/- mice, which
will be conducted on total brain lysate using the OMgp
specific antibody used in aim 3, strategy b, method 2. A
negative control will be conducted on cell extracts from
liver cells, and the loading control for the assay will be
conducted by analyzing the MBP protein expression in
both wild type and Nogo-A/Nogo-B/OMgp-/-/- mice using
the MBP specific antibody aim 3, strategy b, method 2.
Expected Results
We expect to see signals for OMgp expression n wild
type mice, while observing no bands in brain and cell
extracts of Nogo-A/Nogo-B/OMgp-/-/- mice (Fig. 26). We
also expect expression of MBP in both wild type and
Nogo-A/Nogo-B/OMgp-/-/- mice for the loading control.
Strategy B: Verifying the genotype of the Nogo-
A/Nogo-B/Omgp-/-/-  Knockout Mice in vivo
Method 1: General Brain Histology
The histological analysis for testing the structural
integrity and functionality of the triple knockout mice will
be conducted on the cerebral cortex, cerebellum, and
corpus callosum as explained in aim 1, strategy b,
method 1. The expression of the β-galactosidase gene
in the fusion gene construct will be investigated using
X-gal staining as described in aim 1, strategy b, method
1.
Expected Results
We expect to observe expression of OMgp in wild type
cells and no expression in Nogo-A/Nogo-B/OMgp-/-/-
mice (Fig. 27).  We expect expression of the β -
galactosidase protein in all the cells analyzed, which
will indicate successful introduction of the gene
construct (Fig. 27).
Method 2: Rotarod Test
The rotarod test will be used to assess the functional
recovery of locomotor activity of knockout mice
compared to the wild type mice, which will be
conducted as explained in aim 1, strategy c, method 2.
Expected Results
We expect the rotarod test to demonstrate relatively
equal time spend by wild type and knockout mice,
which would demonstrate normal behavior of the Nogo-
A/Nogo-B/Omgp-/-/- mice (Fig. 28).
Strategy C:  In Vitro Investigation of the Nogo-
A/Nogo-B/Omgp-/-/-  Knockout Mice.
The in vitro studies explained in aim 1, strategy c,
method 1 & 2 will be repeated on the triple knockout
mouse.
Method 1: Neurite Outgrowth Assay
As explained in prior sections, the neurite outgrowth
assay is used to study axonal growth in a culture.
Expected Results
Extensive axonal sprouting is expected to occur in
cultures containing myelin derived from both young and
old Nogo-A/Nogo-B/Omgp-/-/- mice, as well as in the
control. Considering that these, cultures are devoid of
the major axonal growth inhibitors such as Nogo-A,
Nogo-B and OMgp.
Method 2: Growth Cone Collapse Assay
The growth cone collapse assay measures the extent to
which axons will branch, by assaying the number of
growth cones is a culture.
Expected Results
We expect to see several growth cones in both younger
(6-11 weeks) and old (>11 weeks) Nogo-A/Nogo-
B/OMgp-/-/- mice.
Strategy D: In Vivo Investigation of the Nogo-
A/Nogo-B/Omgp-/-/- Knockout Mice
In this part of the study, we will investigate axonal
regeneration following SCI in younger (6-11 weeks) and
older (>11 weeks) Nogo-A/Nogo-B/OMgp-/-/- mice using
BDA injections as explained for the coronal and sagittal
studies for young and old Nogo-A/B-/- mice in aim 1,
strategy d, method. For rostral and caudal
investigations, coronal sections at the T4 and C8
vertebrae of the spinal cord will be observed for rostral
and caudal investigations respectively.
Expected Results
a) Coronal Studies
We expect to observe extensive axonal sprouting
rostral and caudal in both ipsilateral and contralateral
orientations to the SCI. We do not expect any axonal
regeneration to occur in wild type mice.
b) Sagittal Studies
The trajectory of axonal sprouting around the SCI is
expected to occur both rostral and caudal in both
ipsilateral and contralateral directions in both young and
old Nogo-A/Nogo-B/OMgp-/-/- mice.  No sprouting is
expected to occur for wild type mice.
Aim four:  The creation of transgenic mice to
overexpress OMgp
Rational:  Since OMgp expression is increasing with
age in Nogo-A/B-/- mice, we want to determine whether
increasing the expression of OMgp in Nogo-A/B-/- mice
will decrease the regeneration of axons, and whether
this decrease will be dependant on age.  It is necessary
to create a transgenic mouse with a different promoter
for the OMgp gene so that the protein will be over
expressed. Once the mice have been created, we will
conduct western blot to check the presence of the
induced gene construct. The mice will then be tested for
axonal regeneration sagittaly and coronally using BDA
injections into the cerebral cortex as explained in aim 1,
strategies c & d.
Strategy A:  Creation of transgenic Nogo-A/B-/- mice
with overexpression of OMgp
Method
We will use our Nogo-A/B-/- mice created in aim 1 as
the basis for our transgenic study.  The transgene will
be created using the OMgp gene with an
oligodendrocyte specific promoter for the Myelin Basic
Protein (MBP) gene (Chen et al, 1999), which will then
be put into a vector.  An ampicillin resistance gene will
also be added, so that the cells containing the
transgene (OMgp++) can be selected for on ampicillin
containing media.  The altered gene will then be
introduced into a line of mouse embryonic stem (ES)
cells, and the transgene will randomly insert itself into
the ES cell genomes through homologous
recombination.  These ES cells will be injected into a
fertilized egg, several of which are then implanted into a
pseudopregnant mouse.  The resulting offspring will be
tested for the presence of the gene within their germ
cells. The mice testing positive will then be used to
study, because all of their progeny will also contain the
transgene, and 25% will be homozygous.
Expected Results
The mice containing the transgene within their germ-
line cells will be bred together to produce offspring.  Of
these offspring 25% are expected to be homozygous
for the transgene based on Mendelian genetics (Fig.
33).  The homozygous mice will then be used for further
studies.
Strategy B:  Verification of transgenic Nogo-A/B-/-
mice with over expression of OMgp in vitro
Method 1: Western blotting
Western blotting will be used to prove the presence of
OMgp is greater in the transgenic mice.  The western
blots will be preformed according to standard procedure
(Amersham Biosciences) using the OMgp specific
antibody (Wang et al., 2003). The loading control
will be conducted using MBP and MAG antibodies (Kim
et al., 2003) and the negative control will be conducted
on liver cells using the OMgp antibody.
Expected Results
We expect that the mice we create will not produce any
Nogo-A or Nogo-B, and the levels of OMgp within the
oligodendrocytes will be significantly higher than the
control mice. The western blots should show a much
more intense band for OMgp in the experimental mice
(Fig. 34).  Other proteins common to myelin are myelin
associated glycoprotein (MAG) and myelin basic protein
(MBP), which are used here to display that increased
OMgp production is not affecting the production levels
of other proteins within the oligodendrocytes. For the
loading control, we expect equal amount of expression
in the wild type and experimental mice and we do not
expect any signal for OMgp, MBP or MAP in liver cells.
Strategy B:  Verification of transgenic Nogo-A/B-/-
mice with over expression of Omgp in vivo
Method 1: General Brain Histology
Histology will be tested to prove the molecular
composition of the mice is the same, and it will be done
using hemotoxylin and eosin stains (Kim et al., 2003) to
view the neuronal make up of the cerebral cortex and
cerebellum. The assays will be conducted as explained
in aim I, strategy c, method 1.
Expected Results
The neuronal make up of the brain should be
unaffected by the overexpression of OMgp.  This will be
shown by analysis of general brain histology (Fig. 35).
The cellular compositiion of the cerebral cortex does
not appear different in WT mice compared to mice
expressing normal OMgp levels and mice
overexpressing OMgp (Fig. 35 A-C).  Parasagittal
sections of the cerebellum demonstrate similar results,
as no significant difference is seen (35 D-F).
Strategy C:  In Vitro Investigation of the Transgenic
Mice that overexpresses OMgp.
OMgp is produced by oligodendrocytes, which
compose the myelin sheath surrounding axons. To
investigate the differential effects of the overexpression
of OMgp we will compare the growth of wild type axons
in cultures containing myelin derived from OMgp+ and
OMgp++-Nogo-A/B-/- mice to the culture without axonal
growth inhibitors. We will use two different assays for
this investigation:
Method 1: Neurite Outgrowth Assay
This test is designed to view the sprouting of axons
from cell bodies on control media containing no myelin
and compare the sprouting to axons grown on myelin
derived from OMgp+Nogo-A/B-/- and OMgp++-Nogo-A/B-
/- mice.  The assay will be conducted as explained in
aim 1, strategy c, method 1.
Expected Results
 The control mice should show no extensive sprouting
because they are not being grown on myelin, and thus
are not subjected to any inhibitory factors.  Extensive
sprouting should also be seen on the plate containing
myelin of the genotype OMgp+-Nogo-A/B-/- due to the
lack of Nogo to inhibit sprouting (Fig. 36).  The plate
with myelin of the genotype OMgp++-Nogo-A/B-/- should
show very little sprouting due to the overexpression of
OMgp inhibiting growth (Fig. 36).
Method 2:  Growth Cone Collapse Assay
This test is designed to examine whether the neurons
are forming synapses with other neurons by evaluating
the number of growth cones visible.  The test is
performed the same way as the neurite outgrowth
assay described above, except that the growth cones
are viewed instead of axons sprouting from cell bodies.
The assay will be conducted as explained in aim 1,
strategy c, method 1.
Expected Results    
The cells on the control plates should show a
substantial number of growth cones, due to the lack of
inhibitory factors.  The cells on the OMgp+-Nogo-A/B-/-
myelin should also show a significant number of growth
cones because of the lack of Nogo-A/B.  The cells on
the OMgp++-Nogo-A/B-/- myelin should show no growth
cones, since OMgp is being overexpressed and
replacing Nogo as the major inhibitor of neural
regeneration (Fig. 37 D-F).
Strategy D: In Vivo Investigation of the OMgp
Knockout Mice
Method
Similar to the in vivo techniques used in aim 1, strategy
d, SCI was introduced in T7 and the resulting axonal
sprouting was investigated using BDA injections at sites
rostral and caudal to the SCI (Kim et al., 2003). For
rostral and caudal investigations, coronal sections at




For the coronal sections rostral to injury site at T4, the
BDA dye should mark the corticospinal tract clearly.
The WT mice should show no axonal sprouting, the
OMgp+-Nogo-A/B-/- mice should show axonal sprouting
both ipsilateral and contralateral to the CST (Fig. 38B &
E), and the OMgp++-Nogo-A/B-/- mice should show no
axonal sprouting, the same as displayed by the WT
mice (Fig. 38A-C).
The caudal sections will not show a
prominent marking of the vCST.  The WT mice will
display no axonal sprouting, the OMgp+-Nogo-A/B-/- will
show axonal growth both contralateral and ipsilateral to
injection site, and the OMgp++-Nogo-A/B-/- mice will
show no axonal growth, in a pattern similar to that of
the WT mice (Fig. 38D-F)
b) Sagittal Studies
Sagittal sections of the SC are viewed for WT, OMgp+-
Nogo-A/B-/- and OMgp++-Nogo-A/B-/- (Fig. 39).  The WT
mouse shows an axon labeled by BDA running to just
before the injury site at T7.  No growth is seen either
rostral or caudal to the injury site, which is due to the
presence of Nogo.  The OMgp+-Nogo-A/B-/- shows
axonal sprouting both ipsilateral and contralateral, as
well as running past the site of injury.  The OMgp++-
Nogo-A/B-/- mouse shows no axonal sprouting, due to
the overexpression of OMgp.
Strategy E: Investigation of the Locomotory Activity
of the Transgenic Mice
We considered whether the over expression of OMgp
inhibits the recovery patterns observed by Strittmatter
et al in Nogo-A/B-/- through the BBB test and was
conducted as explained in aim 1, strategy e.
Expected Results
The OMgp++-Nogo-A/B-/-mice are expected to score
significantly lower on the BBB test than are the OMgp+-
Nogo-A/B-/- mice, due to the added inhibition of axonal
sprouting by the overexpression of OMgp+.  However,
some recovery, following a similar pattern as the
OMgp+ mice is expected (Fig. 40).  This result is
expected because Strittmater et al saw this result when
comparing Nogo-A/B-/- mice to WT mice on the same
scale.  Since the OMgp+-Nogo-A/B-/- mice are the same
as the Nogo-A/B-/- mice and the OMgp++-Nogo-A/B-/-
mice display similar regeneration to WT mice, the BBB
results should also correspond.
Conclusion
Revolutionary studies by Steven Strittmatter (Kim et al.,
2003) and Martin Schwab (Simonen et al., 2003) shows
immense potential in developing genetic techniques
that could inactivate axonal growth inhibitors of the
CNS for initiating axonal regeneration. Nevertheless,
the existence of the Nogo-controversy (Clifford, 2003)
in the field had generated great suspicion in the
consistency of the aforementioned studies. Our study
aims to resolves the controversy in the field with in the
next six to eight years by hypothesizing that Nogo-A/B
and OMgp act as inhibitors of axonal regeneration in
younger and older respectively. We expect that each
knock out transgenic model system proposed in our
study can be established and studied in 12-20 months.
The expected findings should reveal the mystery behind
modest axonal regeneration in the Schwab`s mice and
in the older (>11 weeks) mice of Strittmatter (Kim et al.,
2003). Thus, the study has the potential to initiate new
lines of research to elucidate the unknown factors that
inhibits axonal regeneration in older mammals.
However, we think that the application of the expected
findings of the proposal and even the experimental
findings of Strittmatter (Kim et al., 2003) into therapeutic
techniques needs further investigation. Since, the
results that we expect and that had been shown by
Strittmatter (Kim et al., 2003) do not recover the
damaged synaptic connection, but instead resulted in
non-directional axonal sprouting.
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Figure 1. Strategy for creating Nogo-A/B-/- knockout from Nogo-A- knockout
(A) Schematic representation of the Nogo gene and its major protein products, Nogo-A, Nogo-B, and Nogo-C
(B) Schematic representation of the region of the genome covering exon 1 of the Nogo-B-specific portion of the Nogo gene, and the Nogo-
A/B-/- knockout construct.  This diagram shows the replacement of the Nogo-B gene by the IRES-_-geo and Neomycin-resistant  (pGK-
NEO) genes.  Dotted lines connect homologous sequences of Nogo-B.  The various restriction sites (RS) are shown, and restriction
enzymes are referred to as letters A and B.
  G-> Wild Type Mice
  A-> Mice with cells
  containing the fusion
     gene
A                      B
Figure 2. Creation of A1 & A2 Generation Mice
Fig. 2A: A1 generation: Cross of Wild type Mice (G) & the offspring of the Pseudo-pregnant mice (A) produces 50% homozygous mice
(GA). Fig. 2B: A2 generation: Cross between A1 generation mice (GA) produces 25% homozygous mice (AA).
Figure 3. Southern blot analysis of mouse DNA
The 3’ probe should identify the larger and smaller bands generated by restriction enzyme A.  The wild type (+/+) and control (-/+) mice
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Figure 4.  Northern blot analysis of mRNA expression
The WT and Control mice should hybridize with the Nogo-B probe, producing bands for Nogo-B RNA.  Negative control and knockout mice
should show no bands. Bands should be produced for β-actin in all cell types.
Figure 5.  Western blot analysis of mouse strains
The anti-Nogo antibody should only hybridize with proteins of wild type (WT) and Nogo-A-
mice only, while the Nogo-A/B-/- lane should run blank to indicate the absence of any Nogo-B protein.  The MAG protein should be
highlighted in each lane.
Wild Type            Nogo-A-         Nogo-A/B-/-                       
                                                       6A         6B       6C
                                             Wild Type     Nogo-A-              Nogo-A/B-/-
                                                                 6D      6E  6F
                                                           Wild Type       Nogo-A-  Nogo-A/B-/-
                      6G       6H     6I
Figure 6.  General Brain Histology in Nogo-A/B-/- Mice
(A-C) Coronal sections of the cerebral cortex, stained with hematoxylin and eosin (A and B) or X-gal (C).
(D, E, and G-I) Parasagittal cerebellar sections stained with hematoxylin and eosin (D and E), Luxol fast blue (G and H), or X-gal (I) (F)


















Figure 7. Rotarod Test
Reports the time mice were able to remain on the rotating rod at constant acceleration
 Control                             Nogo-A-                 Nogo-A/B-/-
Figure 8: Neurite Outgrowth Assay
Should indicate the presence of more extensive neurite outgrowth in myelin derived from Nogo-A/B-/- (C) and control (A) mice when
compared to Nogo-A- (B). Arrows point to extending axons.
Wild Type         Nogo-A-             Nogo-A/B-/-
Figure 9. Growth Cone Collapse Assay
Should demonstrate more extensive growth cone collapse in Nogo-A- control mouse axons (B) compared to Nogo-A/B-/- experimental
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Coronal Sections at C8
10D 10E 10F
Figure 10. CST Fiber Sprouting Following SCI in Coronal Sections of T4 and C8
More pronounced (larger quantity) and extensive (further projecting) axonal sprouting is expected to occur in coronal sections of the Nogo-
A/B-/- mouse T6 and C6 spinal cords (C & F compared to sprouting observed in the Nogo-A- mouse spinal cord (B & E).  No sprouting
should be observed in Wild Type mice (A, D)
   11A Wild Type
  11 B Nogo-A-
  11C Nogo-A/B-/-
Figure 11. Sagittal Sections of the Injury Site
More pronounced and extensive sprouting is expected to occur in Sagittal sections of the Nogo-A/B-/- mouse spinal cord (11C) compared to
sprouting observed in the Nogo-A- mouse spinal cord (11B).  No sprouting should be observed in Wild Type mice (11A).
Wild Type Mice Nogo-A- Mice Nogo-A/B-/- Mice














Figure 12. Improved Functional Recovery in Nogo-A/B Knockout Mice
Nogo-A/B-/- mice are expected to regain open-field locomotor performance (hind-limb function) to a much greater extent, at a more
accelerated speed, and at an earlier post injury period than Nogo-A- mice.
Figure 13. Northern blot analysis of mRNA expression
The probe should hybridize more strongly with increased age to account for age-dependant inhibition seen in Strittmatter’s Nogo-A/B-/-
mice. The loading control (ß-actin mRNA) should appear consistent in all mouse ages.
Figure 14. Western blot analysis of protein synthesis
The OMgp antibody should bind more strongly with adult mice compared to younger mice. Myelin Basic Protein should have consistent
expression in all mouse ages.
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Figure 15. Immunohistochemisty analysis
OMgp protein expression should be evident in the spinal cord (A, B, and C) cerebral cortex (D, E, and F), cerebellum (G, H, and I) and
corpus callosum (J, K and L) of all ages of mice. OMgp should immunofluoresce by primary and secondary antibodies in larger quantities
as age of mice increases, to account for age-dependant inhibition. OMgp should not immunofluoresce in lung tissue (M, N and O).
15A. WT (6 week) SC
15G. WT (6 week) Cerebellum
15D. WT (6 week) Cerebral Cortex
15J. WT (6 week) Corpus Callosum
15B. WT (11 week) SC
15E. WT (11 week) Cerebral Cortex
15H. WT (11 week) Cerebellum
15K WT (11 week) Corpus Callosum
 15C. WT (14 week) SC
15F. WT (14 week) Cerebral Cortex
15I. WT (14 week) Cerebellum
15L. WT (14 week) Corpus Callosum
15M. WT (6 week) Lung 15N. WT (11 week) Lung 16N. WT (11 week) Lung
Figure 16. In situ hybridization analysis.
OMgp protein expression should be evident in the spinal cord (A, B and C), cerebral cortex (D, E and F), cerebellum (G, H and I), and
corpus callosum (J, K and L) of all ages of mice. OMgp should be increasingly tagged by its probe as age of mice increases to account for
age-dependant inhibition. OMgp should not be expressed in lung tissue (M, N and O).
Figure 17A. Northern Blot analysis for OMgp in OMgp knockout mice.
The blot shows the absence of the respective mRNA strand in OMgp-/- mice. β-actin is transcribed in both types of mice.
Figure 18: Western Blot Analysis for OMgp Protein.
The blot should show the complete absence of the OMgp protein in brain extracts and liver cells of the knockout mice and the expression of
MBP protein in both wild type and knock out mice.
16A. WT (6 week) SC
16G. WT (6 week) Cerebellum
16D. WT (6 week) Cerebral Cortex
16J. WT (6 week) Corpus Callosum
16B. WT (11 week) SC
16E. WT (11 week) Cerebral Cortex
16H. WT (11 week) Cerebellum
16K. WT (11 week) Corpus Callosum
16C. WT (14 week) SC
16F. WT (14 week) Cerebral Cortex
16I. WT (14 week) Cerebellum
16L. T (14 week) Corpus Callosum
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                Wild Type         OMgp-/-     OMgp-/- (X-Gal)
 19G    19H  19I
Figure 19. General Brain Histology
Coronal section of cerebral cortex stained with hematoxylin and eosin (A & B) and X-Gal (C). Parasagittal Sections of the cerebellum with
hematoxylin and eosin (D andE). Coronal section of cerebellum stained with luxol fast blue (G & H) and X-Gal (I).  Coronal section of
corpus callosum stained with X-gal (F).
Figure 20. Rotarod testing on Wild type & OMgp Knockout Mice
The test should show that the retention time for the wild type and the knockout mice are nearly the same.
                           Control           OMgp-/- (Old)     OMgp-/- (Young)
                    21A            21B 21C
Figure 21: Neurite Outgrowth Assay.
The control (A) should show excessive neurite outgrowth due to the absence of any axonal growth inhibitors. The culture with myelin from
OMgp-/- older mice (B) should show extensive branching of axons and very little branching should be observed in the culture with myelin
from OMgp-/- younger mice (C).
Time on
Rotarod(s)
 Wild Type     OMgp-/-
     400
      100
      200
  300
     Control                        OMgp-/- (Old)                      OMgp-/-(Young)
                                     22D            22E              22F
Figure 22. Growth Cone Collapse Assay.
The control (22A) is expected to demonstrate excessive axonal growth.  The culture containing myelin from OMgp-/- older mice (22B) is
expected to demonstrate extensive branching of axons, with very little branching occurring in the culture with myelin from OMgp-/- younger
mice (22C).
Figure 23. CST Fiber Sprouting Following SCI in Coronal Sections of T4 & C6.
Red arrows indicate corticospinal tract injection with BDA from the cerebrum at the contralateral position of the spinal cord. Extensive
axonal sprouting (indicated by black arrows) is expected to be observed in older OMgp-/- mice (B & E) rostral and caudal to SCI, where as
none should be observed in younger OMgp-/- and wild type mice (A, C, D, and F). The arrows also indicate that the axonal sprouting is
taking place both ipsilateral and contralateral to the site of SCI.
Wild Type Mice OMgp-/- Older Mice OMgp-/-Young Mice
Coronal Sections at T4
Fig. 23A Fig.23B Fig.23C
Coronal Sections at C8












Figure 24.CST Fiber Sprouting Following SCI in Sagittal Sections.
Red arrows and the green arrows indicate the injury site at T6 and the corticospinal tract stained with BDA respectively. The sagittal
sections of the older OMgp-/- mice are expected to demonstrate extensive axonal sprouting (indicated by black arrow) rostral and caudal to
SCI (H) while no sprouting in younger OMgp-/- mice should occur (I). Fig.24H should also indicate that axonal sprouting is taking place both
ipsilateral and contralateral to SCI.
Figure 25: Northern Blot analysis for OMgp in OMgp knockout mice.
The blot should contain signal for OMgp mRNA in wild type mice but not Nogo-A/Nogo-B/OMgp-/-/- mice. Signals for β-actin protein should
be observed in both the wild type and triple mutant mice.
Figure 26: Western Blot Analysis for OMgp Protein.
The blot should indicate the presence of signals for OMgp in wild type mice and absence of signals for Nogo-A/Nogo-B/OMgp-/-/- mice.  The
blot should also display the presence of the loading control protein MBP in both wild type and Nogo-A/Nogo-B/OMgp-/-/- mice.
Sagittal Sections at SCI Site
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Figure 27: General Brain Histology.
Coronal sections of cerebral cortex, stained with hematoxylin (A), eosin (B), and X-Gal (C). Parasagittal Sections of the Cerebellum  are
stained with hematoxylin (D), eosin (E), and with Luxol fast blue (G & 27 H). Coronal section of Corpus Callosum with hematoxylin (G),
eosin (H), and X-Gal ( I).
Figure 28.  Rotarod test
The plot is expected to demonstrate that equal amounts of time are spent on the rotarod by wild type and Nogo-A/Nogo-B/OMgp-/-/- mice.
             Control                                 Nogo-A/Nogo-B/                   Nogo-A/Nogo-B/
           OMgp-/-/- (Old)                OMgp-/-(Young)
                29A 29B 29C
Figure 29. Neurite Outgrowth Assay
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Figure 30. Growth Cone Collapse Assay
The assay is expected to demonstrate extensive branching of axons (indicated by red arrows) in cultures with myelin derived from both
older and younger Nogo-A/Nogo-B/OMgp-/-/- mice (E & F), in addition to the control culture (D).
Coronal Sections at C8
Fig. 31D Fig.31E Fig.31F
Figure 31. Coronal Sections of T2 & C6
Red arrows indicate corticospinal tract injection with BDA from the cerebrum at the contralateral position of the spinal cord. Extensive axonal sprouting
(indicated by black arrows) should be observed in older and younger Nogo-A/Nogo-B/OMgp-/-/- mice (Fig.31B, 31C, 31E& 31F) rostral and caudal to
SCI. The arrows also indicate that the axonal sprouting is taking place both ipsilateral and contralateral to the SCI site.
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Figure 32. Sagittal Sections of the injury site.
Red arrows and green arrows indicate the injury site at T6 and the corticospinal tract stained with BDA respectively. The sagittal sections of
the older and younger Nogo-A/Nogo-B/Omgp-/-/- mice are expected to demonstrate extensive axonal sprouting (indicated by black arrow)
rostral and caudal to SCI (H & I), while no sprouting should occur in wild type mice (G). Fig.32H should also indicate that axonal sprouting
takes place at both and contralateral and ipsilateral levels
Figure 33. Crossing of two mice heterozygous for the OMgp++ transgene
A capital O represents a WT allele, and a lower case o represents an allele containing the transgene.  The 25% of the progeny represented
in the lower right cell of the table are the homozygous mice to be studied.
        WT  OMgp+ Nogo-A/B-/-         OMgp++-Nogo-A/B-/-     Liver Cells





Figure 34.  Western Blot analysis of OMgp levels in transgenic and control mice.
The wild type mouse should produce the same level of OMgp as the Nogo-A/B-/- mouse, but the level of OMgp in the OMgp+/+Nogo-A/B-/-
should be significantly higher. The level of MAG should remain constant in all three mice, as should the level of MBP.





















        Wild Type       OMgp+ Nogo-A/B-/-  OMgp++-Nogo-A/B-/-
          35A  35B          35C
        Wild Type         OMgp+-Nogo-A/B-/-    OMgp++-Nogo-A/B-/-
       35D        35E        35F
Figure 35. General Brain Histology
General Brain histology should demonstrate no defects in the structural integrity of the brain. A-C: Coronal sections through the cerebral
cortex stained with hematoxylin and eosin.  The neuronal makeup should be the same.  D-F:  Parasagittal sections through the cerebellum,
stained with hematoxylin and eosin.  Again, the similar cellular makeup will show that there is no difference in the neuronal composition of
the brains despite the varying expression levels of OMgp.
Control                 OMgp+-Nogo-A/B-/-       OMgp++-Nogo-A/B-/-
Fig. 36A           Fig. 36B                         Fig. 36C
Figure 36 A-C.  A:  Cells on the control plate should show extensive axonal growth from the cell bodies, indicated by arrow.  B: Cells on the
OMgp+-Nogo-A/B-/- myelin should show axonal growth due to the lack of inhibitory factors, indicated by arrow.  C: Cells on OMgp++-Nogo-
A/B-/- myelin are expected to display axonal growth due to the overexpression of OMgp.  The protocol for the assay will be adapted from
Strittmatter et al (Kim et al., 2003).
                    Control                       OMgp+-Nogo-A/B-/-        OMgp++-Nogo-A/B-/-
Fig. 37D   Fig. 37E   Fig. 37F
Figure 37 D-F. Growth Cone Collapse Assay  D:  The cells on the control plates should show the presence of growth cones, indicated by
arrow.  E:  The cells on OMgp+-Nogo-A/B-/- myelin should show a large number of visible growth cones similar to the control, indicated by
arrow.  F:  The cells on OMgp++-Nogo-A/B-/-  are expected to show low numbers of growth cones compared to the control and the OMgp+-
Nogo-A/B-/-.
Wild Type Mice OMgp+-Nogo-A/B-/- OMgp++-Nogo-A/B-/-
Coronal Sections at T4
Fig. 38A Fig.38B Fig.38C
Coronal Sections at L2
Fig. 38D Fig.38E Fig.38F
Figure 38. Coronal Sections at T4 and L2.
A:  Section at T4 of WT mouse, no axonal sprouting should be seen.  B:  Section at T4 of OMgp+-Nogo-A/B-/- mouse, axonal sprouting is
expected to be seen both contralateral and ipsilateral to injury site.  C:  Section at T4 of OMgp++-Nogo-A/B-/- mouse, no axonal sprouting
ought to be seen, which is the same as the WT result.  D:  Section at L2 of WT mouse, no axonal is supposed to be seen.  E:  Section at L2
of OMgp+-Nogo-A/B-/- mouse, where axonal sprouting is seen both contralateral and ipsilateral to the injection site.  F:  Section at L2 of
OMgp++-Nogo-A/B-/-    
Figure 39: Sagittal Sections of the injury site.
The injury (red arrow) is marked by a small triangle on the dorsal side of the spinal cord.  The axons of the CST (green arrow) are seen
running along the dorsal half of the spinal cord and are marked by arrows.  G:  The WT mice are expected to show no axonal growth
leading up to or past the injury site.  H:  The OMgp+-Nogo-A/B-/- mice should show axonal sprouting (black arrow) rostral to the injury site
and running more than 5mm caudal to it.  Also, sprouting is seen both on the ipsilateral and contralateral side.  I:  The OMgp++-Nogo-A/B-/-
mice ought to show no axonal sprouting either rostral or caudal to the injury site, much like the WT mice.
Sagittal Sections at SCI Site
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Figure 40.  Quantification of BBB.
Score (x-axis) in relationship to days post injury.  All mice were between 7-9 weeks of age at the time of SCI, and their gain of functionality
was monitored daily.  The OMgp++ mice are supposed to regain function in a pattern similar to that of the OMgp+ mice, but do not should not
recover as fully.
OMgp+-Nogo-A/B-/-
OMgp++-Nogo-A/B-
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